Format

Send to

Choose Destination
Klin Padiatr. 2001 Nov-Dec;213(6):338-42.

[Safety of an influenza-split-vaccine in children].

[Article in German]

Author information

1
Zentrum für Kinderheilkunde, Rheinische Friedrich-Wilhelms-Universität Bonn, Germany.

Abstract

BACKGROUND:

The aim of this study was to investigate the safety of the split-product influenza vaccine Begrivac(R), containing the recommended virus strains for the influenza season 1998/99.

PATIENTS:

Eighty-three children aged 6 months - 12 years were enrolled in the study.

METHODS:

Adverse events (AEs) were reported for up to 21 days after the last immunization. A hemagglutination assay was performed of blood samples taken before and after vaccination.

RESULTS:

Only mild (40 %) to moderate and mainly local reactions (redness, swelling, induration and pain) were reported. Seroprotection after the first immunisation was reached against influenza strain A (H1N1) in 75 % of the vaccinees, against strain A (H3N2) in 83 % and against strain B in 33 %. After the second immunisation, 96 % of the population achieved seroprotection against A (H1N1), 100 % against A (H3N2) and 96 % against B.

CONCLUSIONS:

The influenza split vaccine is safe and effective in children.

PMID:
11713714
DOI:
10.1055/s-2001-18464
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Georg Thieme Verlag Stuttgart, New York
Loading ...
Support Center